Cargando…

Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review

Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or H...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashita, Shunya, Eguchi, Yuichiro, Mizuta, Toshihiko, Kuroki, Shigetaka, Ono, Naofumi, Eguchi, Takahisa, Anzai, Keizo, Fujimoto, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652303/
https://www.ncbi.nlm.nih.gov/pubmed/23704814
http://dx.doi.org/10.3164/jcbn.13-8
_version_ 1782269307631173632
author Nakashita, Shunya
Eguchi, Yuichiro
Mizuta, Toshihiko
Kuroki, Shigetaka
Ono, Naofumi
Eguchi, Takahisa
Anzai, Keizo
Fujimoto, Kazuma
author_facet Nakashita, Shunya
Eguchi, Yuichiro
Mizuta, Toshihiko
Kuroki, Shigetaka
Ono, Naofumi
Eguchi, Takahisa
Anzai, Keizo
Fujimoto, Kazuma
author_sort Nakashita, Shunya
collection PubMed
description Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or HCC or lung cancer admitted to a municipal hospital in Japan; 48 had liver cirrhosis, 35 HCC and 33 lung cancer. By retrospective chart review, we evaluated: (i) rate of usage of narcotic analgesics and (ii) survival time from onset of coma (Glasgow Coma Scale less than 8). Time between coma and death was significantly shorter in the liver disease patients (cirrhosis and/or HCC: 7.0 h) than in lung cancer (44.0 h, p = 0.045). Total bilirubin was higher in HCC compared with cirrhosis (p<0.01). Rate of usage of narcotic analgesics was higher in lung cancer (20/33: 60.6%) than in liver disease (17/83: 20.5%, p<0.01); analgesics were used more frequently in HCC than in liver cirrhosis (p<0.01). These results suggest that liver cirrhosis and HCC patients do not always require palliative care and that survival time from onset of coma due to liver disease was not prolonged compared with lung cancer.
format Online
Article
Text
id pubmed-3652303
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-36523032013-05-23 Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review Nakashita, Shunya Eguchi, Yuichiro Mizuta, Toshihiko Kuroki, Shigetaka Ono, Naofumi Eguchi, Takahisa Anzai, Keizo Fujimoto, Kazuma J Clin Biochem Nutr Original Article Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or HCC or lung cancer admitted to a municipal hospital in Japan; 48 had liver cirrhosis, 35 HCC and 33 lung cancer. By retrospective chart review, we evaluated: (i) rate of usage of narcotic analgesics and (ii) survival time from onset of coma (Glasgow Coma Scale less than 8). Time between coma and death was significantly shorter in the liver disease patients (cirrhosis and/or HCC: 7.0 h) than in lung cancer (44.0 h, p = 0.045). Total bilirubin was higher in HCC compared with cirrhosis (p<0.01). Rate of usage of narcotic analgesics was higher in lung cancer (20/33: 60.6%) than in liver disease (17/83: 20.5%, p<0.01); analgesics were used more frequently in HCC than in liver cirrhosis (p<0.01). These results suggest that liver cirrhosis and HCC patients do not always require palliative care and that survival time from onset of coma due to liver disease was not prolonged compared with lung cancer. the Society for Free Radical Research Japan 2013-05 2013-05-01 /pmc/articles/PMC3652303/ /pubmed/23704814 http://dx.doi.org/10.3164/jcbn.13-8 Text en Copyright © 2013 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Nakashita, Shunya
Eguchi, Yuichiro
Mizuta, Toshihiko
Kuroki, Shigetaka
Ono, Naofumi
Eguchi, Takahisa
Anzai, Keizo
Fujimoto, Kazuma
Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title_full Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title_fullStr Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title_full_unstemmed Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title_short Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
title_sort evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652303/
https://www.ncbi.nlm.nih.gov/pubmed/23704814
http://dx.doi.org/10.3164/jcbn.13-8
work_keys_str_mv AT nakashitashunya evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT eguchiyuichiro evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT mizutatoshihiko evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT kurokishigetaka evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT ononaofumi evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT eguchitakahisa evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT anzaikeizo evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview
AT fujimotokazuma evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview